Navigation Links
NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Date:10/31/2007

SAN MATEO, Calif., Oct. 31 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing novel pain management therapies, announced today that it is scheduled to present on Monday, November 5, 2007 at the CIBC World Markets 18th Annual Healthcare Conference and on Tuesday, November 6, 2007 at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference. Anthony DiTonno, President and Chief Executive Officer, will be presenting and Stephen Ghiglieri, Chief Financial Officer, will be available to respond to questions during the break out sessions.

Event: CIBC World Markets 18th Annual Healthcare Conference

Date: Monday, November 5, 2007

Time: 11:30 a.m. ET

Place: The Waldorf-Astoria Hotel, New York

Event: Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

Date: Tuesday, November 6, 2007

Time: 10:55 a.m. ET

Place: New York Palace Hotel, New York

An audio Web cast of the Company's presentations will be available by going to the investor relations section of NeurogesX' Web site at http://www.neurogesx.com. A replay of the presentation will be available for 15 days.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy. NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies. Three Phase 3 clinical trials with NGX-4010 have been completed and have met their primary endpoints, two in PHN and one in painful HIV-DSP.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the timing of presentations by NeurogesX and the expected benefits of NeurogesX' potential products, including its lead product candidate NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, past results of clinical trials may not be indicative of future clinical trials results; NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010 and the advantages of NGX-4010 over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX The Ruth Group

Stephen Ghiglieri Investors / Media

(650) 358-3310 Stephanie Carrington / Jason Rando

sghiglieri@neurogesx.com (646) 536-7017 / 7025

scarrington@theruthgroup.com

jrando@theruthgroup.com


'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... 2017   Boston Biomedical , an industry leader ... cancer stemness pathways, will feature data from two clinical ... 2017 ASCO Gastrointestinal Cancers Symposium, held from January 19-21, ... Napabucasin is an orally-administered investigational agent designed to ... Cancer stem cells (CSCs) possess the property of stemness ...
(Date:1/18/2017)...   Parent Project Muscular Dystrophy (PPMD) , a ... muscular dystrophy (Duchenne) , today announced a $600,000 grant ... Technology (NJIT) and Talem Technologies (Talem) as part of ... to assist people living with Duchenne. PPMD is funding ... embedded computer, software, a force sensor and a motor ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... Dante Leven successfully implanted SpineFrontier’s A-CIFT™ Solofuse-P™. The operation took place on Wednesday, ... Stream, NY. The procedure was an anterior cervical discectomy and fusion on a ...
(Date:1/18/2017)... Frederick, Maryland (PRWEB) , ... January 18, 2017 ... ... of two new federally funded bio-focused Manufacturing Innovation Institutes (MII). U.S. Secretary of ... Innovation in Manufacturing Biopharmaceuticals (NIIMBL), and the Department of Defense has announced the ...
Breaking Biology Technology:
(Date:1/18/2017)... , Jan. 18, 2017  In vitro diagnostic (IVD) ... mergers and acquisitions (M&A), and Kalorama Information expects that ... acquisitions have been shifting. Generally, uncertainty in reimbursement and ... the U.S. has changed the acquisitions landscape. Instead of ... in companies buying partners outside of their home country ...
(Date:1/12/2017)... NEW YORK , Jan. 12, 2017  New research ... around the office of the future.  1,000 participants were simply ... last three months which we may consider standard issue.  Insights ... office of 2017 were also gathered from futurists and industry ... and Dr. James Canton .  Some ...
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, Inc., ... in healthy volunteers of a novel calcium release-activated ... acute pancreatitis. Acute pancreatitis, sudden ... mild disorder, but can be very serious.  In severe ... sepsis, where extended hospital stays, time in the ...
Breaking Biology News(10 mins):